SG11201407768QA - Generating pluripotent cells de novo - Google Patents

Generating pluripotent cells de novo

Info

Publication number
SG11201407768QA
SG11201407768QA SG11201407768QA SG11201407768QA SG11201407768QA SG 11201407768Q A SG11201407768Q A SG 11201407768QA SG 11201407768Q A SG11201407768Q A SG 11201407768QA SG 11201407768Q A SG11201407768Q A SG 11201407768QA SG 11201407768Q A SG11201407768Q A SG 11201407768QA
Authority
SG
Singapore
Prior art keywords
lllll
international
hirosawa
saitama
riken
Prior art date
Application number
SG11201407768QA
Inventor
Charles A Vacanti
Martin P Vacanti
Koji Kojima
Haruko Obokata
Teruhiko Wakayama
Yoshiki Sasai
Masayuki Yamato
Original Assignee
Brigham & Womens Hospital
Riken
Univ Tokyo Womens Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Riken, Univ Tokyo Womens Medical filed Critical Brigham & Womens Hospital
Publication of SG11201407768QA publication Critical patent/SG11201407768QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 31 October 2013 (31.10.2013) WIPOIPCT (10) International Publication Number WO 2013/163296 A1 (51) International Patent Classification: C12N 5/07 (2010.01) A61K 48/00 (2006.01) C12N 5/02 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/037996 24 April 2013 (24.04.2013) English (30) Priority Data: 61/637,631 61/779,533 24 April 2012 (24.04.2012) 13 March 2013 (13.03.2013) English US US (71) Applicants: THE BRIGHAM AND WOMEN'S HOS­ PITAL, INC. [US/US]; 75 Francis Street, Boston, Mas­ sachusetts 02115 (US). RIKEN [ JP/JP] ; 2-1, Hirosawa, Wako-Shi, Saitama, 351-0198 (JP). TOKYO WOMEN'S MEDICAL UNIVERSITY [JP/JP]; 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 (JP). (72) Inventors: VACANTI, Charles A.; 355 Pond Street, Uxbridge, Massachusetts 01569 (US). VACANTI, Martin P.; 2220 Westchester Drive #6, Manhattan, Kansas 66503 (US). KOJIMA, Koji; 50 Longwood Avenue #414, Brookline, Massachusetts 02446 (US). OBOKATA, Haruko; c/o RIKEN, 2-1, Hirosawa, Wako-shi, Saitama, 351-0198 (JP). WAKAYAMA, Teruhiko; c/o RIKEN, 2- 1, Hirosawa, Wako-shi, Saitama, 351-0198 (JP). SASAI, Yoshiki; c/o RIKEN, 2-1, Hirosawa, Wako-shi, Saitama, 351-0198 (JP). YAMATO, Masayuki; c/o Tokyo Wo­ men's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 (JP). (74) Agents: RESNICK, David et al.; Nixon Peabody LLP, 100 Summer Street, Boston, Massachusetts 02110-2131 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, [Continued on next page] (54) Title: GENERATING PLURIPOTENT CELLS DE NOVO 0\ CJ 40%i 35%- 30%- CO LU 25%- CJ + o_ 20%- CD *d- o 15%- c=> 10%- i i r « L T 9 o%- • //// (57) Abstract: The technology de­ scribed herein relates to methods, as­ says, and compositions relating to caus­ ing a cell to assume more pluripotent a state, e.g. without introducing foreign genetic material. ^ i ~—i ~—r J® i-H o CJ o & WO 2013/163296 A11 lllll llllllll II llllll III lllll lllll lllll III III III lllll lllll lllll lllll llll llll lllllll llll llll KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, FT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201407768QA 2012-04-24 2013-04-24 Generating pluripotent cells de novo SG11201407768QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637631P 2012-04-24 2012-04-24
US201361779533P 2013-03-13 2013-03-13
PCT/US2013/037996 WO2013163296A1 (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo

Publications (1)

Publication Number Publication Date
SG11201407768QA true SG11201407768QA (en) 2015-01-29

Family

ID=49483852

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407768QA SG11201407768QA (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo
SG10201809901SA SG10201809901SA (en) 2012-04-24 2013-04-24 Generating Pluripotent Cells De Novo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201809901SA SG10201809901SA (en) 2012-04-24 2013-04-24 Generating Pluripotent Cells De Novo

Country Status (11)

Country Link
US (1) US11963977B2 (en)
EP (2) EP2844738A4 (en)
JP (4) JP2015516812A (en)
KR (2) KR20200084916A (en)
CN (2) CN112048466A (en)
AU (2) AU2013251649B2 (en)
CA (1) CA2885576A1 (en)
ES (1) ES2972525T3 (en)
RU (1) RU2696071C2 (en)
SG (2) SG11201407768QA (en)
WO (1) WO2013163296A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3260140B1 (en) 2011-12-05 2021-02-03 Factor Bioscience Inc. Methods and products for transfecting cells
KR20230154283A (en) 2012-11-01 2023-11-07 팩터 바이오사이언스 인크. Methods and products for expressing proteins in cells
WO2014117021A2 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
EP2955223B1 (en) 2013-02-08 2019-12-18 Kyoto University Production methods for megakaryocytes and platelets
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US9624471B2 (en) 2013-06-12 2017-04-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN105940110A (en) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 Methods and products for nucleic acid production and delivery
MX2016012102A (en) * 2014-03-19 2017-02-20 Vcell Therapeutics Inc Methods relating to pluripotent cells.
WO2016089178A1 (en) * 2014-12-04 2016-06-09 가톨릭관동대학교산학협력단 Device and method for inducing pluripotent cells using energy
KR101798726B1 (en) * 2014-12-04 2017-11-16 가톨릭관동대학교기술지주 주식회사 Device and method for inducing pluripotency cells yielded by energy
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017155166A1 (en) * 2016-03-11 2017-09-14 가톨릭관동대학교기술지주 주식회사 Cell reprogramming method using imposition of physical stimulation-mediated environmental transition
WO2017155167A1 (en) * 2016-03-11 2017-09-14 가톨릭관동대학교산학협력단 Cell reprogramming apparatus
KR101855967B1 (en) * 2016-03-11 2018-05-10 가톨릭관동대학교산학협력단 Physical stimulation-mediated permeation of Environmental transition guided cellular reprogramming
KR102050852B1 (en) * 2016-03-11 2019-12-03 주식회사 스템온 Device for cell reprogramming
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA3043166A1 (en) * 2016-11-07 2018-05-11 K2 Research Holdings, Llc Production and therapeutic uses of epinul pluripotent cells and differentiated cells derived therefrom
EP3601530A1 (en) * 2017-03-20 2020-02-05 IFOM Fondazione Istituto Firc di Oncologia Molecolare Method of generating 2 cell-like stem cells
WO2018226435A1 (en) * 2017-06-10 2018-12-13 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN107729932B (en) * 2017-10-10 2019-07-26 杭州智微信息科技有限公司 Bone marrow cell labeling method and system
KR102416171B1 (en) 2018-10-02 2022-07-06 주식회사 스템온 Reprosomes, the exosomes capable of inducing reprogramming of cells and the preparation method thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US12091684B2 (en) 2020-02-14 2024-09-17 Hackensack Meridian Health, Inc. Platelet-derived mitochondria treatment and method of generating multipotent cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
FR2687404B1 (en) 1992-02-19 1994-05-20 Centre Nal Recherc Scientifique IMMUNOLOGICALLY RELATED PEPTIDES TO PROTEINS OF A VIRAL AGENT AND THEIR BIOLOGICAL APPLICATIONS.
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
PT671923E (en) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc FIGURE RESERVE CELLS
US5753431A (en) * 1993-10-13 1998-05-19 Northeastern Ohio University Cholesterol 7 α-hydroxdylase gene regulatory elements and transcription factors
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
GB0113118D0 (en) 2001-05-31 2001-07-18 Intercytex Ltd Stem Cells
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
CN101065478B (en) * 2003-12-02 2012-07-04 塞拉维生物科学公司 Compositions and methods for propagation of neural progenitor cells
US20090104158A1 (en) * 2004-09-03 2009-04-23 Moraga Biotechnology Corporation Non-Embryonic Totipotent Blastomere-Like Stem Cells And Methods Therefor
US20060084167A1 (en) 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
US20090298095A1 (en) * 2005-04-15 2009-12-03 The John Hopkins University Immortalization of cells including neuronal cells
FR2885368A1 (en) * 2005-05-04 2006-11-10 Fred Zacouto Treating cells genetically/epigenetically to treat diseases, involves contacting nucleus of to-be-treated cell with genetic reprogramming medium having natural cytoplasm of genetic reprogramming cell, to modify biological age
CA2621161A1 (en) * 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20070190646A1 (en) 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
US20090252711A1 (en) * 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
WO2008066630A2 (en) * 2006-10-27 2008-06-05 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods for reprogramming adult somatic cells and uses thereof
CA3071055A1 (en) * 2007-04-07 2008-10-16 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
WO2009058884A1 (en) * 2007-10-30 2009-05-07 Le Centre Nationale De La Recherche Scientifique Method for conducting an assay for neutralizing antibodies
EP2096169B1 (en) * 2007-10-31 2020-11-18 Kyoto University Nuclear reprogramming method
US20090280518A1 (en) * 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
EP2492715B1 (en) * 2009-10-06 2019-01-09 Canon Kabushiki Kaisha Rear attachment lens, imaging optical system, and image pickup apparatus
EP2554659A4 (en) 2010-04-02 2013-09-25 Riken Method for preparing es cells
KR20120002134A (en) 2010-06-30 2012-01-05 서울대학교산학협력단 Method for dedifferentiations of adipose tissue stromal cells
EP2590695A4 (en) 2010-07-09 2017-09-06 The Gid Group, Inc. Apparatus and methods relating to collecting and processing human biological material containing adipose

Also Published As

Publication number Publication date
EP3483261B1 (en) 2023-11-29
CA2885576A1 (en) 2013-10-31
CN112048466A (en) 2020-12-08
RU2696071C2 (en) 2019-07-30
AU2013251649A1 (en) 2014-11-06
CN104718283A (en) 2015-06-17
EP3483261A1 (en) 2019-05-15
JP2015516812A (en) 2015-06-18
JP2023002805A (en) 2023-01-10
US11963977B2 (en) 2024-04-23
AU2019203943A1 (en) 2019-06-27
AU2013251649B2 (en) 2019-04-04
SG10201809901SA (en) 2018-12-28
EP2844738A4 (en) 2015-12-23
KR20200084916A (en) 2020-07-13
AU2019203943B2 (en) 2021-10-07
EP2844738A1 (en) 2015-03-11
KR20150045935A (en) 2015-04-29
ES2972525T3 (en) 2024-06-13
RU2014147093A (en) 2016-06-10
US20150110749A1 (en) 2015-04-23
JP2020182480A (en) 2020-11-12
JP2018183145A (en) 2018-11-22
WO2013163296A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
SG11201407768QA (en) Generating pluripotent cells de novo
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201806988UA (en) Improved differentiation method
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201408261UA (en) Syringe
SG11201406943XA (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407221TA (en) Assembly of wafer stacks
SG11201907846VA (en) Therapeutic rna
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407427WA (en) Extreme pcr
SG11201408236UA (en) Dynamic pressure control in a battery assembly
SG11201407702XA (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407200TA (en) Liquid formulation
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201806453TA (en) Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models
SG11201406625XA (en) Anti-fcrn antibodies
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201901628XA (en) Methods and compositions for spinal cord cells